Soleno Therapeutics to Participate in Upcoming June Conferences

Soleno Therapeutics (SLNO) will present at the Jefferies Global Healthcare Conference on June 4th at 10:30 AM ET and the Goldman Sachs 46th Healthcare Conference on June 10th at 8:40 AM ET. These presentations will provide an update on the company's progress, particularly regarding VYKAT™ XR, its treatment for hyperphagia in Prader-Willi syndrome, and may influence investor sentiment.

Analysis

Soleno Therapeutics (NASDAQ: SLNO) has announced its planned participation in two significant investor conferences in June 2025: the Jefferies Global Healthcare Conference on June 4th and the Goldman Sachs 46th Healthcare Conference on June 10th, where it will deliver corporate presentations. These events represent key opportunities for the biopharmaceutical company to update the investment community on its progress, particularly concerning its lead commercial product, VYKAT™ XR. VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is highlighted as the company's first commercial product, a once-daily oral treatment for hyperphagia in adults and children aged four and older with Prader-Willi syndrome, aligning with Soleno's stated focus on developing and commercializing novel therapeutics for rare diseases. While the announcement of conference participation itself carries a neutral general sentiment (score 0.0) and a low market impact score (0.1), the content of the presentations could influence investor perception, as suggested by the slightly positive per-ticker sentiment for SLNO (0.1). Access to replays on the company’s website will facilitate broader dissemination of the information shared during these corporate updates.

Key Decisions for Investors

• Investors should monitor Soleno Therapeutics' corporate presentations at the upcoming Jefferies and Goldman Sachs healthcare conferences in June for critical updates on VYKAT™ XR's commercialization strategy, any new clinical data, and revised management guidance.
• The information disseminated during these conferences, especially details regarding VYKAT™ XR, could serve as a near-term catalyst for SLNO's stock, warranting close attention to assess potential impacts on the company's valuation.
• It is advisable to review the webcast replays, which will be available on Soleno's investor relations website, to directly evaluate the substance of the presentations and management's commentary on the company's outlook.